Key Insights

Highlights

Success Rate

83% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

5.3%

5 terminated out of 95 trials

Success Rate

83.3%

-3.2% vs benchmark

Late-Stage Pipeline

4%

4 trials in Phase 3/4

Results Transparency

20%

5 of 25 completed with results

Key Signals

5 with results83% success

Data Visualizations

Phase Distribution

49Total
Not Applicable (32)
Early P 1 (2)
P 1 (6)
P 2 (5)
P 3 (1)
P 4 (3)

Trial Status

Recruiting33
Completed25
Not Yet Recruiting23
Active Not Recruiting5
Terminated5
Enrolling By Invitation3

Trial Success Rate

83.3%

Benchmark: 86.5%

Based on 25 completed trials

Clinical Trials (95)

Showing 20 of 20 trials
NCT05384080CompletedPrimary

A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Poland

NCT07368972Phase 2RecruitingPrimary

Study of DISC-0974-201 in Participants With IBD and Anemia

NCT06989424Not ApplicableNot Yet RecruitingPrimary

Visualization of the Colon Through Use of the Magnetic Flexible Endoscope (MFE) in Participants With Inflammatory Bowel Disease (IBD)

NCT07423000Phase 1RecruitingPrimary

A Phase 1 Study of PVT401 in Healthy Subjects

NCT07089771Not ApplicableNot Yet RecruitingPrimary

Virtual Versus Dye-based Chromoendoscopy in Inflammatory Bowel Disease Surveillance Colonoscopy

NCT07237516Recruiting

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

NCT07477782Phase 2Not Yet Recruiting

Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis - Randomized Study Versus Sham Transplantation

NCT07113522Phase 2RecruitingPrimary

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

NCT07123350Active Not RecruitingPrimary

Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease

NCT06877923Not ApplicableRecruiting

Elemental 028 Extra Case Studies

NCT07411131Not ApplicableNot Yet RecruitingPrimary

A Pilot Study on the Efficacy and Safety of a Novel Synbiotic Formula (SGR11) in Patients With Inflammatory Bowel Disease (IBD)

NCT07245394RecruitingPrimary

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

NCT07400211Not Yet RecruitingPrimary

Diagnosis of Inflammatory Bowel Disease

NCT07385131RecruitingPrimary

Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD

NCT06502873Not ApplicableRecruitingPrimary

Setting up a Cohort of Patients With Inflammatory Bowel Disease and a Cohort of Patients Without Chronic Inflammatory Bowel Disease

NCT04806620Recruiting

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

NCT07355101Not ApplicableActive Not RecruitingPrimary

Personalized Exercise Coaching to Improve Quality of Life in Pediatric IBD

NCT07237984Not Yet Recruiting

Colorectal Omics and ofCS Proteoglycans (COCO) in Screening and a Diagnostic Pathway

NCT07343726Not Yet RecruitingPrimary

Impact of Obesity on Response to Therapy and Clinical Outcom in Patients With Inflammatory Bowel Disease

NCT07318753Not ApplicableActive Not RecruitingPrimary

A Clinical Study on The Use of DL-endopeptidase-producing Probiotics as an Adjunctive Therapy for Inflammatory Bowel Disease.

Scroll to load more

Research Network

Activity Timeline